key: cord-0699772-iscf6bz1
authors: Finsterer, Josef
title: Exacerbation of diabetic neuropathy can mimic SARS-CoV-2 associated pure dysautonomic Guillain–Barre syndrome
date: 2022-02-25
journal: J Neurovirol
DOI: 10.1007/s13365-022-01055-6
sha: 88ac360700c5d116870c95f138b03f978e6d08a9
doc_id: 699772
cord_uid: iscf6bz1

nan

To the Editor, With interest we read the article by year-old male who developed pure dysautonomic Guillain-Barre syndrome (GBS) 10 days after onset of moderate COVID-19 (Biassoni et al. 2021) . Dysautonomic manifestations included urinary retention and orthostatic dysfunction (Biassoni et al. 2021) . The patient had a previous history of diabetes and arterial hypertension (Biassoni et al. 2021) . We have the following comments and concerns.

A limitation of the study is that information about diabetes in the index patient is missing. We should know the onset of diabetes, quality of diabetes control, medication, number of hypoglycaemic or hyperglycaemic episodes, and if there were any indications for diabetic neuropathy prior to onset of COVID-19. Missing in this respect are the HbA1c values, results of previous nerve conduction studies (NCSs), and ophthalmologic investigations. It is unclear how exacerbation of diabetic neuropathy due to the viral infection was excluded.

We do not agree with the classification of GBS as pure dysautonomic. Since nerve conduction velocity of motor nerves was reduced, there was at least electrophysiological involvement of motor nerves.

Missing are systematic investigations for autonomic dysfunction. We should be told if there was REM sleep behaviour disorder, reduced heart rate variability, oversensitivity to light, renal dysfunction, bowel dysfunction, impotentia, anaemia, syncope, left ventricular hypertrophy, arterial hypertension, postprandial hypotension, constipation, or hyper-or hypohidrosis. Assuming that there was indeed pure dysautonomic GBS, why should only be the urinary bladder and the orthostatic reaction be involved and not the entire spectrum of autonomic functions? One would expect that more autonomic functions were impaired.

We should be informed why the patient received insulin during hospitalisation. Obviously, diabetes worsened during the viral infection, why it is conceivable that autonomic dysfunction was rather due to worsening diabetic neuropathy than GBS.

GBS is usually diagnosed according to the Brighton criteria. However, when applying these criteria, level 1 of certainty was not reached, further suggesting that there was diabetic neuropathy rather than GBS.

Missing are follow-up investigations, to assess if intravenous immunoglobulins truly exhibited a beneficial effect. Particularly missing are electrophysiological follow-up investigations to assess if neuropathy improved with clinical improvement.

Overall, this interesting case report has limitations which should be addressed before attributing partial autonomic dysfunction to SARS-CoV-2 associated GBS. In a patient with diabetes, which worsened during the infection with SARS-CoV-2, autonomic dysfunction is rather attributable to exacerbating diabetic neuropathy than GBS.

The importance of thinking about Guillain-Barré syndrome during the COVID